Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283586 | 1.00 | ITGAL (0.35) | ITGALAPPMEN1KMT2ACYP1A2 | |
| SCHEMBL13879675 | 0.74 | ITGAL (0.40) | ITGALMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL13879673 | 0.73 | ITGAL (0.54) | ITGALMAPTALDH1A1 | |
| SCHEMBL13879679 | 0.73 | SMN1; SMN2 (0.41) | ITGALMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL13879684 | 0.72 | MAOB (0.39) | ITGALMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL28240259 | 0.72 | TDP1 (0.40) | APPCYP1A2CYP2C19MAPTHTT | |
| SCHEMBL13879687 | 0.71 | MAOB (0.40) | ITGALMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL13879682 | 0.71 | ITGAL (0.56) | ITGALALDH1A1 | |
| SCHEMBL13879669 | 0.71 | ITGAL (0.54) | ITGAL | |
| SCHEMBL30584115 | 0.68 | NFKB1 (0.59) | MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ITGAL 4495/4885APP 4226/4885MEN1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.